Research Article
CD8+ TIL Recruitment May Revert the Association of MAGE A3 with Aggressive Features in Thyroid Tumors
Table 2
Immunohistochemical expression of MAGE A3, according to clinicopathological features of aggressiveness, patient’s outcome, and immunological markers.
| | Clinicopathological features (%) | Quantitative analysis (ACIS)
Median | value |
| | Gender | Female (82) | 90.100 | 0.0016 | | Male (18) | 72.770 |
| | Ethnicity | White (96) | 91.230 | 0.9069 | | Nonwhite (4) | 74.480 |
| | Age | 45 years old (58) | 77.055 | 0.0272 | | 45 years old (42) | 92.290 |
| | Tumor size | <2 cm (48) | 77.590 | 0.6526 | | 2–4 cm (25) | 83.065 | | >4 cm (37) | 95.510 |
| | Extrathyroidal invasion | Yes (56) | 89.490 | 0.0206 | | No (44) | 69.060 |
| | Capsulation | Yes (33) | 77.590 | 0.9570 | | No (67) | 79.650 |
| | Multifocality | Yes (41) | 79.745 | 0.3918 | | No (59) | 79.120 |
| | Metastasis at diagnosis | Present (15) | 83.065 | 0.9774 | | Absent (85) | 79.120 |
| | Disease stage (TNM) | I (63) | 77.325 | 0.0107 | | II (8) | 93.570 | | III (12) | 83.380 | | IV (17) | 92.540 |
| | Outcome | Free of disease (15) | 79.840 | 0.3475 | | Recurrent (85) | 98.410 |
|
|
